Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Total Liabilities (2016 - 2025)

China Pharma Holdings filings provide 16 years of Total Liabilities readings, the most recent being $8.3 million for Q4 2025.

  • On a quarterly basis, Total Liabilities rose 15.69% to $8.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $8.3 million, a 15.69% increase, with the full-year FY2025 number at $8.3 million, up 15.69% from a year prior.
  • Total Liabilities hit $8.3 million in Q4 2025 for China Pharma Holdings, up from $7.5 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $16.6 million in Q4 2021 to a low of $6.9 million in Q2 2024.
  • Median Total Liabilities over the past 5 years was $10.3 million (2021), compared with a mean of $10.6 million.
  • Biggest five-year swings in Total Liabilities: increased 26.83% in 2021 and later tumbled 39.63% in 2024.
  • China Pharma Holdings' Total Liabilities stood at $16.6 million in 2021, then dropped by 18.87% to $13.5 million in 2022, then plummeted by 33.2% to $9.0 million in 2023, then fell by 20.8% to $7.1 million in 2024, then grew by 15.69% to $8.3 million in 2025.
  • The last three reported values for Total Liabilities were $8.3 million (Q4 2025), $7.5 million (Q3 2025), and $7.3 million (Q2 2025) per Business Quant data.